FDA-approved generic pergolide reaches equine PPID market

CURRENT FULL VERSION: A new FDA-approved generic pergolide option is now available for horses with pituitary pars intermedia dysfunction, better known as PPID or equine Cushing’s disease. Dechra’s Zygolide was approved on December 19, 2025, with FDA announcing the approval on January 9, 2026, making it the first generic drug approved for control of clinical signs associated with PPID in horses. FDA said the product is bioequivalent to Prascend, the brand-name pergolide tablet first approved in 2011. (animaldrugsatfda.fda.gov)

That matters because PPID is one of the most common endocrine disorders in older horses, and treatment is often lifelong. In its launch announcement, Dechra cited estimates that PPID affects about 21% of horses age 15 and older, with prevalence rising in more advanced age groups. Clinical management can be straightforward in principle, but in practice it often depends on whether a horse will reliably take a daily tablet, whether the dose can be adjusted precisely, and whether the cost remains sustainable for the pet parent over months or years. (dechra-us.com)

The approved product is a 1 mg pergolide tablet packaged in blister cards, with cartons of 60 or 160 tablets. According to the FDA freedom of information summary, the labeled starting dose is 2 mcg/kg orally once daily, with dose adjustments to effect and a maximum of 4 mcg/kg daily. As an abbreviated new animal drug application, Zygolide did not have to re-establish the full safety and effectiveness profile from scratch; instead, Dechra had to show bioequivalence to the reference listed drug, Prascend. FDA’s summary says the sponsor conducted an in vivo blood-level study in horses and reported no serious adverse events during that study. (animaldrugsatfda.fda.gov)

Dechra is also trying to differentiate the product on practical features, not just generic status. Company materials highlight peppermint flavoring, 360-degree scoring to simplify splitting, and packaging intended to support tablet stability and dosing accuracy. The Horse advertising materials published in 2026 extend that message in a more emotional, owner-facing way, with taglines such as “Rediscover the partnership with Zygolide” and “Help your horse feel their best so you can enjoy more happy moments together.” Those points come from promotional sources, so they should be read as positioning rather than independent proof of better adherence or outcomes, but they align with a real clinical pain point in PPID management: getting a senior horse to accept medication every day while preserving quality of life for both horse and owner. (dechra-us.com)

Industry coverage has largely focused on access and affordability. Dechra’s equine medical affairs lead, Greg Schmid, said in the company announcement that the approval brings “a high-quality, cost-effective option” to market and emphasized the tablet’s scoring and flavor profile. dvm360’s coverage echoed that framing, centering the launch as a generic alternative that may broaden access for horses requiring chronic therapy. The Horse placements suggest Dechra is also investing in direct awareness-building around the horse-owner bond and the everyday experience of managing PPID, not just the economics of switching to a generic. Independent expert commentary beyond trade coverage appears limited so far, which is not unusual this soon after a product launch. (dechra-us.com)

Why it matters: For veterinary professionals, the biggest significance is less about a new mechanism and more about expanding the treatment toolkit within an FDA-approved category. PPID patients are often older horses with concurrent issues, including laminitis risk, weight changes, and management challenges that demand close follow-up. A generic pergolide option could help practices reduce cost-related treatment gaps, especially in horses that need higher doses or long-term titration. It may also reduce reliance on less standardized workarounds when pet parents struggle with price or administration. At the same time, clinicians will still need to counsel carefully on adverse effects, appetite changes, handling precautions, and the instruction not to crush tablets because of human exposure concerns. The owner-directed language appearing in The Horse ads is also a reminder that treatment decisions in PPID are often emotional as well as clinical, shaped by a desire to maintain comfort, function, and the horse-human relationship over time. (fda.gov)

There are also some practical caveats. While Dechra promotes palatability and tablet design, real-world uptake will depend on pharmacy availability, actual price spread versus Prascend, and whether horses that have resisted other pergolide formulations truly do better on this one. The core clinical expectations remain familiar: monitor response, adjust dose to effect, and keep client communication tight around appetite loss, weight changes, lethargy, and behavior changes that can emerge during treatment. The ad campaign’s emphasis on “happy moments” and partnership may resonate with owners, but clinicians will still want to anchor conversations in measurable response and realistic expectations. (dechra-us.com)

What to watch: Over the next several months, watch for formulary adoption by equine practices and online pharmacies, early clinician feedback on adherence and dosing convenience, and whether generic competition meaningfully shifts the economics of long-term PPID care in the U.S. market. It will also be worth watching whether Dechra’s owner-facing campaign in The Horse helps drive awareness and uptake among clients managing senior horses with chronic endocrine disease. (dechra-us.com)